BEPREVE (bepotastine besilate ophthalmic solution) 1.5% provides relief for ocular itch associated with the signs and symptoms of allergic conjunctivitis ALREX (loteprednol etabonate ophthalmic suspension) 0.2% provides multisymptom relief for acute seasonal allergic conjunctivitis
Image of eyes depicting many Americans suffer from ocular allergies, yet few seek medical attention

Image of eyes depicting many Americans suffer from ocular allergies, yet few seek medical attention = 1 million Americans

Yet, only about 10% of individuals with allergic conjunctivitis seek medical attention.5

*Based on 2014 and 2016 reviews of prevalence trends in allergic ocular diseases.

When it comes to treating patients’ allergies, allergic
conjunctivitis is often underdiagnosed and its
symptoms overlooked4,6

Bausch + Lomb Access Program prescription copay offer

Help your eligible patients save on
ALREX and BEPREVE

With the Bausch + Lomb Access Program, eligible insured patients pay no more than $35 co-pay on 5 mL bottles of ALREX or BEPREVE.

PATIENTS SAVE MORE DURING ALLERGY SEASON

Eligible commercially insured patients pay no more than $10 co-pay on 5 mL bottles of ALREX and BEPREVE during the spring and fall allergy seasons.

Spring savings offer available February 15 through June 15.
Fall savings offer available August 1 through October 31.

This co-pay offer applies to the first prescription and up to 6 refills.

Eligible patients can download and activate a Bausch + Lomb Access card by visiting bauschaccessprogram.com.

  • Patients who receive a physical co-pay card in office can activate online at blsavings.com, on the phone by calling 1-866-693-4880, or by texting BLSAVINGS to 24109.
  • Once the card has been downloaded or activated, patients can take it to Walgreens or a participating independendent pharmacy to pick up their prescription.
  • Discount pricing is also available for eligible uninsured patients.

Terms and conditions apply. See eligibility criteria and terms and conditions at bauschaccessprogram.com
‡Message and data rates may apply. The full terms can be viewed at bauschaccess.copaysavingsprogram.com/sms-terms.

 

 

Indication

ALREX® (loteprednol etabonate ophthalmic suspension) 0.2% is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.

Important Safety Information
  • ALREX is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of the ocular structures. ALREX is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.
  • Prolonged use of ALREX is associated with several warnings and precautions, including glaucoma with optic nerve damage, defects in visual acuity, cataract formation, secondary ocular infections, exacerbation or prolongation of viral ocular infections (including herpes simplex), delay in wound healing and increase in bleb formation.
  • If this product is used for 10 days or longer, intraocular pressure should be monitored. The initial prescription and renewal of the medication order beyond 14 days should be made by a physician only after reexamination of the patient with the aid of magnification. Fungal infections of the cornea may develop with prolonged use of corticosteroids.
  • Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2% - 0.5%) in clinical studies included abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia.

Click here for Prescribing Information for ALREX.

Indications and Usage

BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis.

Important Safety Information
  • BEPREVE is contraindicated in patients with a history of hypersensitivity reactions to bepotastine or any of the other ingredients.
  • BEPREVE is for topical ophthalmic use only. To minimize risk of contamination, do not touch the dropper tip to the eyelids or to any surface. Keep the bottle closed when not in use.
  • BEPREVE should not be used to treat contact lens-related irritation. Remove contact lens prior to instillation of BEPREVE. Lenses may be reinserted 10 minutes after BEPREVE administration.
  • The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions occurring in 2%-5% of patients were eye irritation, headache, and nasopharyngitis.

Click here for Prescribing Information for BEPREVE.

References: 1. ALREX [package insert]. Tampa, FL: Bausch & Lomb Incorporated; May 2016. 2. BEPREVE [package insert]. Tampa, FL: Bausch & Lomb Incorporated; June 2016. 3. Gomes PJ. Trends in prevalence and treatment of ocular allergy. Curr Opin Allergy Clin Immunol. 2014;14(5)451-456. 4. Ackerman S, Smith LM, Gomes PJ. Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management. Ther Adv Chronic Dis. 2016;7(1):52-67. 5. Azari AA, Barney NP. Conjunctivitis: a systematic review of diagnosis and treatment. JAMA. 2013;310(16):1721-1729. 6. Bielory L, Katelaris CH, Lightman S, Naclerio RM. Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. MedGenMed. 2007;9(3):35.

Indication

ALREX® (loteprednol etabonate ophthalmic suspension) 0.2% is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.

Important Safety Information
  • ALREX is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of the ocular structures. ALREX is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.
  • Prolonged use of ALREX is associated with several warnings and precautions, including glaucoma with optic nerve damage, defects in visual acuity, cataract formation, secondary ocular infections, exacerbation or prolongation of viral ocular infections (including herpes simplex), delay in wound healing and increase in bleb formation.
  • If this product is used for 10 days or longer, intraocular pressure should be monitored. The initial prescription and renewal of the medication order beyond 14 days should be made by a physician only after reexamination of the patient with the aid of magnification. Fungal infections of the cornea may develop with prolonged use of corticosteroids.
  • Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2% - 0.5%) in clinical studies included abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia.

Click here for Prescribing Information for ALREX.

Indications and Usage

BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis.

Important Safety Information
  • BEPREVE is contraindicated in patients with a history of hypersensitivity reactions to bepotastine or any of the other ingredients.
  • BEPREVE is for topical ophthalmic use only. To minimize risk of contamination, do not touch the dropper tip to the eyelids or to any surface. Keep the bottle closed when not in use.
  • BEPREVE should not be used to treat contact lens-related irritation. Remove contact lens prior to instillation of BEPREVE. Lenses may be reinserted 10 minutes after BEPREVE administration.
  • The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions occurring in 2%-5% of patients were eye irritation, headache, and nasopharyngitis.

Click here for Prescribing Information for BEPREVE.

THIS WEBSITE IS INTENDED FOR U.S. HEALTHCARE PROFESSIONALS ONLY.

Please choose an option below: